Ignite Creation Date:
2024-07-17 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06490068
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-29
Brief Title:
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Study Overview
Official Title:
An Open Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of LTC004 in Combination With Toripalimab in Patients With Advanced Solid Tumors Resistant to First-line Immunotherapy
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of LTC004 in combination with Toripalimab in 10 patients with advanced solid tumors resistant to first-line immunotherapy all eligible subjects will receive LTC004 on day 1 of Week 1 and day 1 of week 3 Beginning at week 5 all subjects will receive LTC004 in combination with Toripalimab regimen until disease progression intolerance informed withdrawal or up to 2 years of dosing whichever occurred first
Detailed Description:
All eligible subjects will receive LTC004 on day 1 of Week 1 and day 1 of week 3 Beginning at week 5 all subjects will receive LTC004 in combination with Toripalimab regimen until disease progression intolerance informed withdrawal or up to 2 years of dosing whichever occurred first
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None